«The significance of the conference to each of us and for pharmaceutical industry in general is obvious. Compliance with GMP standards is a strategy that should be followed for comprehensive and steady development of pharmaceutical industry in the Russian Federation. It is impossible to enter new markets or increase export of domestic products without strict compliance with international quality standards. We have our own course of actions in this endeavor, and are greatly interested in a dialogue with market participants to discuss mutual recognition and EAEU integration into the global system.»As Vladislav Shestakov – Director of the State Institute of Drugs and Good Practices – noted, the GMP conference covers a larger number of issues each year, prompts new business contacts and higher quality levels in pharmaceutical manufacture. It has become a tradition to sign agreements and resolutions for partnership cooperation. On the sidelines of the conference the State Institute of Drugs and Good Practices – that celebrates its 45th anniversary this year –signed a memorandum with the Scientific Centre for Expert Evaluation of Medicinal Products.«Our organizations» profiles are close in nature – we ensure the proper quality of medicines and optimize regulations of their circulation. When two separate components unite, they form a new system with new properties. I believe that the synergy of our efforts will not flatly sum up our resources, but will have a multiplier effect, and will highly likely lead to new ideas that would not otherwise have come to existence,» commented Vladislav Shestakov.
The business agenda of the conference opened with a panel discussion Drivers of pharmaceutical market growth. Global perspective. The Russian Ministry of Industry and Trade, the Federal Service for Health Care Surveillance, the Tatarstan Ministry of Industry and Trade as well as leaders of Russian pharmaceutical business engaged in the discussion. Participants touched on the mechanisms and vectors of development for pharmaceutical industry in Moscow and Tatarstan. They paid special to international practices of market development.
Given the magnitude of Pharma-2030 strategy, recently published for public feedback by the Russian Ministry of Industry and Trade, it plaid the key note in the panel discussion Pharmaceutical industry of the Future. Government and business perspectives. The chosen strategy will determine development of the Russian pharmaceutical industry for the next decade following expiration of the current regulation. Due the high public interest, the participants offered their changes to be included into the strategy.
Almost a thousand participants convened for the first conference day. There are two more ahead: full of hard work, interaction with foreign delegations who will share inspection experience, master classes conducted by leading experts and much more.
Partners of the III All-Russia GMP Conference:
General partner – Valenta Pharm; strategic partners: Gedeon Richter, TatKhimPharmPreparaty JSC; partners of the conference: Astellas Pharma, Takeda Pharmaceuticals, TEVA; partners of the sessions: Akrihin, Amgen, Bosnalijek, PRO.MED.CS Prague a.s., Pharmimeks, Sanofi Russia; special partners: GEROPHARM, NatsImBio.
The conference has been organized by the Russian Ministry of Industry and Trade together with the State Institute of Drugs and Good Practices, the conference is operated by «S-Group» Center for Corporate Communications.